Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR TherapeuticsTM, announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in cognitive dysfunction in schizophrenia. TC-5619 is a novel small molecule that is highly selective for the alpha7 neuronal nicotinic receptor, or NNR, and was discovered by Targacept scientists using Targacept's proprietary drug discovery platform known as PentadTM. "We believe that currently available treatment options do not adequately address the dramatic impact schizophrenia has on cognition for millions of patients.
The 2009 American College of Neuropsychopharmacology Annual Meeting featured innovative research on PTSD, biomarkers for schizophrenia and treatment for gambling addiction. Study highlights included: Researchers Use New Techniques to Assess PTSD. Working with Iraq and Afghanistan veterans, scientists have identified measurable traits that may be useful to evaluate PTSD and develop new treatments. Using blood analysis and brain imaging techniques, scientists have identified possible characteristics, known as candidate biomarkers, for patients with PTSD. Progress in this area could lead to earlier diagnosis and enable individuals to receive personalized treatment strategies, which could greatly improve the therapeutic outcomes for many veterans who have served in the U.
Phase III Study Demonstrates INVEGA R SUSTENNA TM paliperidone Palmitate Statistically Similar To RISPERDAL R CONSTA R risperidone
Treatment with once-monthly INVEGA® SUSTENNA(TM) is not inferior to treatment with bi-weekly RISPERDAL® CONSTA® , according to new data from a comparative study of both treatments in patients with schizophrenia. Results of the 13-week clinical trial were released this week. An estimated one percent of the world's population suffers from schizophrenia - a brain disorder that impairs a person's ability to think clearly, relate to others, and distinguish between reality and imagination. In the U.S., approximately 2.4 million Americans have schizophrenia, with men and women affected equally.(1) Non-adherence to medication treatment is a common problem encountered in patients with schizophrenia, which can lead to relapse (an increase in symptoms) and hospitalization.
The U.S. Food and Drug Administration (FDA) approved Zyprexa® (olanzapine) in tablet form as an option for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adolescents aged 13-17 years old. The updated Zyprexa label states that clinicians should take into consideration the increased potential for weight gain and hyperlipidemia in adolescents compared to adults and the potential for long-term risks, which in many cases, may lead them to consider prescribing other drugs first in adolescents. Compared to patients from adult clinical trials, adolescents were also likely to experience increased sedation and greater increases in prolactin levels and hepatic transaminase (liver enzymes) levels.
Otsuka Pharmaceutical Europe Ltd Withdraws Its Application For An Extension Of Indication For Abilify aripiprazole , Europe
The European Medicines Agency has been formally notified by Otsuka Pharmaceutical Europe Ltd of its decision to withdraw its application for an extension of indication for the centrally authorised medicine Abilify (aripiprazole) tablets, orodispersible tablets and oral solution. Abilify was expected to be used in the treatment of major depressive episodes, as adjunctive therapy, in patients who have had an inadequate response to previous treatment with antidepressants. Abilify was first authorised in the European Union on 4 June 2004. It is currently indicated for the treatment of schizophrenia and for the treatment and prevention of manic episodes in bipolar I disorder.
UCSF scientists studying nerve cells in fruit flies have uncovered a new function for a gene whose human equivalent may play a critical role in schizophrenia. Scientists have known that the mutated form of the human gene - one of three consistently associated with schizophrenia - mildly disrupts the transmission of chemical signals between nerve cells in the brain. The new study focuses on genes involved in "adaptive plasticity, " the capacity of nerve cells to compensate for a wide range of perturbations and continue to function normally. Studies ranging from fruit flies to human have shown that if a nerve cell is functionally impaired then the surrounding cells can compensate and restore normal cell-to-cell communication.